Satellos Bioscience Inc. (MSCLF)
USD 0.62
(-0.06%)
USD 0.62
(-0.06%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.62 Million CAD | 28.05% |
| 2022 | 2.83 Million CAD | 34.51% |
| 2021 | 2.1 Million CAD | 60.21% |
| 2020 | 1.31 Million CAD | 62.61% |
| 2019 | 807.62 Thousand CAD | 0.62% |
| 2018 | 802.67 Thousand CAD | 178.42% |
| 2017 | 288.29 Thousand CAD | 108.57% |
| 2016 | 138.22 Thousand CAD | 19.98% |
| 2015 | 115.21 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 4.02 Million CAD | 7.27% |
| 2024 Q1 | 3.75 Million CAD | 3.59% |
| 2023 Q4 | 3.62 Million CAD | 56.41% |
| 2023 FY | 3.62 Million CAD | 28.05% |
| 2023 Q3 | 2.31 Million CAD | -40.3% |
| 2023 Q2 | 3.88 Million CAD | -21.11% |
| 2023 Q1 | 4.91 Million CAD | 73.83% |
| 2022 Q4 | 2.83 Million CAD | 40.24% |
| 2022 Q2 | 2.08 Million CAD | 32.78% |
| 2022 Q1 | 1.56 Million CAD | -25.45% |
| 2022 FY | 2.83 Million CAD | 34.51% |
| 2022 Q3 | 2.01 Million CAD | -3.1% |
| 2021 Q2 | 9.36 Million CAD | 387.61% |
| 2021 Q1 | 1.92 Million CAD | 46.25% |
| 2021 Q4 | 2.1 Million CAD | -2.96% |
| 2021 FY | 2.1 Million CAD | 60.21% |
| 2021 Q3 | 2.16 Million CAD | -76.85% |
| 2020 Q4 | 1.31 Million CAD | 0.0% |
| 2020 FY | 1.31 Million CAD | 62.61% |
| 2020 Q1 | - CAD | 0.0% |
| 2019 FY | 807.62 Thousand CAD | 0.62% |
| 2018 FY | 802.67 Thousand CAD | 178.42% |
| 2017 FY | 288.29 Thousand CAD | 108.57% |
| 2016 FY | 138.22 Thousand CAD | 19.98% |
| 2015 FY | 115.21 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 93.201% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 62.179% |
| SQZ Biotechnologies Company | 50.03 Million USD | 92.758% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 94.999% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 93.859% |
| Mesoblast Limited | 188.44 Million USD | 98.077% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 5.905% |
| Genus plc | 485 Million USD | 99.253% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 37.973% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -44.019% |
| Marizyme, Inc. | 26.67 Million USD | 86.415% |
| ContraFect Corporation | 32.53 Million USD | 88.86% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 4.632% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -82.909% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 5.32% |
| Intellipharmaceutics International Inc. | 12 Million USD | 69.822% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 69.231% |
| MultiCell Technologies, Inc. | 1617.67 USD | -223925.914% |
| Accustem Sciences Inc. | 1.07 Million USD | -235.792% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.319% |
| EV Biologics, Inc. | 2.11 Million USD | -71.342% |
| Q BioMed Inc. | 8.13 Million USD | 55.44% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.63% |
| Neon Bloom, Inc. | 1.22 Million USD | -195.544% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 29.577% |
| Biomind Labs Inc. | 1.49 Million USD | -141.824% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 98.515% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 80.308% |
| Skye Bioscience, Inc. | 14.07 Million USD | 74.247% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -80.287% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2450.406% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 61.715% |
| IMV Inc. | 37.93 Million USD | 90.446% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1701.945% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 36.928% |
| GB Sciences, Inc. | 5.41 Million USD | 33.106% |
| Alpha Cognition Inc. | 7.16 Million USD | 49.419% |
| HST Global, Inc. | 593.59 Thousand USD | -510.519% |
| CSL Limited | 18.62 Billion USD | 99.981% |
| Halberd Corporation | 728.71 Thousand USD | -397.311% |
| Enzolytics Inc. | 365.26 Million USD | 99.008% |
| Resverlogix Corp. | 67.39 Million USD | 94.623% |
| Affymax, Inc. | 8.87 Million USD | 59.148% |
| SYBLEU INC | 681.41 Thousand USD | -431.836% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -332.081% |
| argenx SE | 444.95 Million USD | 99.186% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.163% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -111.435% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 69.554% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 1.123% |
| AVAX Technologies, Inc. | 3.99 Million USD | 9.258% |
| Zenith Capital Corp. | 27.56 Thousand USD | -13045.199% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.727% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1418.516% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 2.954% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -432.288% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.947% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 59.921% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5314.693% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -152.744% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 92.79% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -33.646% |
| BioStem Technologies, Inc. | 15.9 Million USD | 77.214% |
| ONE Bio Corp. | 27.49 Million USD | 86.82% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -679.86% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -13110.367% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -187.803% |
| Agentix Corp. | 2.51 Million USD | -44.351% |
| LadRx Corporation | 2.2 Million USD | -64.688% |
| Cell Source, Inc. | 15.8 Million USD | 77.073% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -8008.108% |
| Regen BioPharma, Inc. | 5.45 Million USD | 33.597% |
| Regen BioPharma, Inc. | 5.45 Million USD | 33.597% |
| NovAccess Global Inc. | 7.86 Million USD | 53.897% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 85.355% |
| Itoco Inc. | 1.65 Million USD | -119.218% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -76.646% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 40.089% |
| Kadimastem Ltd | 3.5 Million USD | -3.399% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -759.648% |
| CytoDyn Inc. | 127.89 Million USD | 97.166% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -8570.064% |
| Mobile Lads Corp. | 1.31 Million USD | -175.905% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -131.362% |
| Qrons Inc. | 1.48 Million USD | -143.432% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 67.19% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -348.075% |
| Rebus Holdings, Inc. | 5.24 Million USD | 30.866% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 40.609% |
| International Stem Cell Corporation | 5.27 Million USD | 31.325% |
| Bioxytran, Inc. | 3.24 Million USD | -11.525% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -479.09% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 21.51% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 91.16% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 83.723% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -78.929% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 33.844% |
| Neutra Corp. | 973.52 Thousand USD | -272.254% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 87.51% |
| PureTech Health plc | 125.58 Million USD | 97.114% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 3.543% |
| IXICO plc | 1.9 Million USD | -90.708% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 82.347% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.493% |
| CSL Limited | 18.62 Billion USD | 99.981% |
| Cellectis S.A. | 249.36 Million USD | 98.547% |